Heydemann, Ahlke
Bieganski, Grzegorz
Wachowiak, Jacek
Czarnota, Jarosław
Niezgoda, Adam
Siemionow, Krzysztof
Ziemiecka, Anna
Sikorska, Maria H.
Bozyk, Katarzyna
Tullius, Stefan G.
Siemionow, Maria http://orcid.org/0000-0001-6372-6122
Article History
Accepted: 8 March 2023
First Online: 31 March 2023
Declarations
:
: MS is CMO and shareholder of Dystrogen Therapeutics Corp. the company that holds a license for DEC01 Therapy. The author declares a potential conflict of interest. MS is the inventor on the patent application filed by University of Illinois at Chicago related to chimeric cell therapy for Duchenne muscular dystrophy (WO/2016/201182). KS is CEO and shareholder of Dystrogen Therapeutics Corp. AH is the adviser to Dystrogen Therapeutics Corp. The authors declare a potential conflict of interest. GB, JW, JC and AN received fees for work related to this study. AZ, MHS and KB are Dystrogen Therapeutics Corp. employees. SGT declares no competing interests.
: All procedures performed in the study involving human participants were in accordance with the ethical standards of the 1964 Helsinki Declaration and its later amendments and the Good Clinical Practice (GCP) guidelines. The study was approved by the Bioethics Committee at the Regional Medical Council in Poznan, Poland (approval No. 46/2019).
: Freely-given, informed consent to participate in the study was obtained from all participants (or their parent or legal guardian in the case of children under 16). The tissues were obtained in MedPolonia Hospital (Poznan, Poland). No tissues were obtained from prisoners.
: Freely-given, informed consent to publish their data in journal article was obtained from all participants (or their parent or legal guardian in the case of children under 16).